Arkolith/Insider Trading/KTRA/Form 4

Dearborn Dan

Chief Financial OfficerKintara Therapeutics, Inc. (KTRA) · full profile →Form 4 · filed Oct 22, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
0 non-derivative · 5 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 18, 2024Grant(A)34K—$034K
Oct 18, 2024Grant(A)68K—$068K
Oct 18, 2024Grant(A)233K—$0233K
Oct 18, 2024Grant(A)16K—$016K
Oct 18, 2024Grant(A)67K—$067K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000897069-24-001992) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML